Xenografts, tumorgrafts and patient derived xenografts (PDXs) are among the most common models to study human cancer. These models require the implantation in animal hosts (commonly mice) of cancer cells derived from cell lines, primary cancer stem cells or tumor biopsies. Tumorgafts/PDXs were developed almost fifty years ago, but even after the recent development of highly immunodeficient strains of mice that will not reject the implanted cells, positive results from grafting experiments remain uncertain. One promising advance was the finding, almost three decades ago, that the co-injection of Basement Membrane Matrix or Cultrex BME with tumor cells improved tumor take and growth, and since, a number of cell lines have shown increased take and growth when mixed and co-injected with Cultrex BME.
In the past, researchers have used our original formulation of Cultrex BME in their xenograft experiments, now Trevigen offers Cultrex Basement Membrane Matrix BME Type 3 that has been developed, produced, and qualified specifically for use in in vivo studies. Cultrex BME Type 3 mimics the in vivo microenvironment, including increased stiffness, low glucose, and low pH, to improve take rate and growth of implanted cells for xenograft and tumorgraft models.
If you do not have experience growing xenografts or you detect slow or no growth of your tumors, take a look at the resources offered below.
i. Increased initiation and growth of tumor cell lines, cancer stem cells and biopsy material in mice using basement membrane matrix protein (Cultrex or Matrigel) co-injection. Fridman R, Benton G, Aranoutova I, Kleinman HK, Bonfil RD. Nature Protocols, 2012.
ii. NSG mice provide a better spontaneous model of breast cancer metastasis than athymic (nude) mice. Puchalapalli M, Zeng, X, Mu L, Anderson A et al. Plos One, 2016.